The former president of product development at Genentech, Susan Desmond-Hellmann, will be taking up a chancellor post at the University of California, San Francisco, after the Board of Regents votes on her appointment later this week, reports the WSJ Health Blog. Before joining Genentech, Desmond-Hellman trained at UCSF, then practiced as an oncologist. At Genentech, she oversaw the development of Avastin, Herceptin, and Rituxan.
A Pretty Nice Pasture
May 04, 2009